MindRank Showcases AI-Powered Anti-Aging Research Advancements at 2026 Wellcome Leap Dynamic Resilience Investigator Meeting
MindRank
AI Drug Developer
Recently, jointly initiated by Wellcome Leap and Temasek Trust"2026 Wellcome Leap Dynamic Resilience Researcher Conference"Successfully held in Tokyo, Japan.
MindRank Invited to Attend the Conference and Deliver a Special Report, Sharing the Latest Research Achievements in the Anti-Aging Field with World-Renowned Scholars from Oxford University, Cambridge University, Imperial College London, University of Oslo in Norway, and Other Institutions, While Looking Forward to Cutting-Edge Research Directions.
Dynamic Resilience is an internationally leading "AI + anti-aging" collaboration project dedicated to extending human healthspan by developing innovative therapies and drugs.MindRank is responsible for the research and development of the "AI Large Language Model Assisting Anti-Aging Innovative Therapy Development Project" and collaborates with a research team jointly formed by the University of Oslo, the University of Cambridge, and Imperial College London to advance the project implementation.
During the conference, MindRank shared the team's recent research progress: relying on cutting-edge AI technology, MindRank has advanced its original knowledge graph research platform, PharmKGPT.TM On the basis of,Further expand into a comprehensive platform for aging and health resilience research, ResiliNet.The platform focuses on introducing large language models and agent technology to promote the integration, understanding, and reasoning of multimodal data.
During the research process, the team utilized an intelligent system capable of knowledge retrieval, information integration, complex reasoning, and task collaboration to extract insights from a vast amount of literature, omics data, clinical information, and multi-level evidence.The system identifies key resilience factors that influence health outcomes in the elderly, further elucidates the complex mechanisms associated with aging, and provides new technical support for risk prediction, biomarker discovery, and the development of potential intervention strategies.
Looking ahead, MindRank will continue to collaborate with top academic partners worldwide, further exploring innovative applications of AI technology in the field of anti-aging biology.Committed to transforming cutting-edge discoveries into verifiable biomarkers, actionable targets, and innovative therapies with clinical translational potential, enabling more lives to enjoy extended health and vitality.
About MindRank
MindRank is a globally leading AI for drug discovery technology innovation company dedicated to empowering new drug research and development through machine learning, reinforcement learning, and first-principles calculations. Relying on its self-developed one-stop AI platform that deeply integrates biology, structural biology, chemistry, and medicine, it expands the boundaries of pharmaceutical technology, enabling more diseases to have effective treatments and helping more lives regain health.
END
IND Approved | MindRank's Self-developed WEE1/YES1 Dual Inhibitor Receives FDA Clinical Approval
For more information, please visit the website:
www.mindrank.ai
Contact: bd@mindrank.ai pr@mindrank.ai
Other: info@mindrank.ai